Mit Delcath SYS Krebs örtlich bekämpfen
| eröffnet am: | 18.05.10 21:18 von: | Magnetfeldfredy |
| neuester Beitrag: | 24.04.21 23:43 von: | Katharinaqdlka |
| Anzahl Beiträge: | 1847 | |
| Leser gesamt: | 469500 | |
| davon Heute: | 46 | |
bewertet mit 9 Sternen |
||
|
|
||
06.01.17 20:00
#76
Angelman
Was ist hier los
mit dieser beschissenen Aktie - nirgends findet man was wirklich negatives, aber der Kurs schmiert dermaßen ab....... Warum?
Der Alptraum im Depot
Der Alptraum im Depot
09.01.17 06:25
#77
wennichdaswueste
RSI is 16 vllt. kann mir jemand sagen , ob
es auch unter rsi 10 gehen könnte http://stockcharts.com/h-sc/ui?s=DCTH
23.01.17 17:53
#78
Chalifmann3
was ist los,alle aufgegeben ??
Delcath Systems, Inc. (NASDAQ:DCTH) Releases Latest Data From Retrospective Trial Of Melphalan/HDS,
By Ernest Bun • January 20, 2017
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology firm focused on the cure of primary and metastatic liver cancers, reported latest data from a retrospective trial of Melphalan/HDS. The report has been approved for oral presentation at the upcoming Regional Cancer Therapies International Symposium, to be held from February 18 – 20, 2017.
The details
The retrospective trial was performed by Moffitt Cancer Center teams in Tampa and the University of Southampton in the UK. The study assesses patient treatment results with PHP® therapy with Melphalan/HDS in subjects with primary metastatic ocular melanoma with liver metastasis cured between 2008 and 2016. The trial was directed by Dr. Alexandra Gangi.
Delcath CEO Jennifer K. Simpson, Ph.D. said that they are extremely delighted that Dr. Gangi and respective team’s research has been approved for oral presentation at this prominent event and consider that their research report will further inform on the application of Melphalan/HDS as a prospective viable additional alternative for cure of hepatic metastases in people with metastatic ocular melanoma. They look forward to reporting the details of new report after it is presented.
Delcath is an interventional oncology firm focused on advancing the therapies for primary and metastatic liver cancers. The investigational product, Melphalan Hydrochloride for application with the Delcath Hepatic Delivery System, is intended to provide high-dose chemotherapy to the liver, and at the same time controlling systemic exposure and related side effects.
The company has initiated an international Phase III FOCUS clinical study for subjects with Hepatic Dominant Ocular Melanoma and an international Phase II clinical study in the U.S. and Europe to probe the Melphalan/HDS system for the cure of primary liver cancer and intrahepatic cholangiocarcinoma. Melphalan/HDS has not been accepted by the U.S. FDA for sale in the U.S.
In the last trading session, the stock price of Delcath declined more than 24% to close the day at $0.310.
By Ernest Bun • January 20, 2017
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology firm focused on the cure of primary and metastatic liver cancers, reported latest data from a retrospective trial of Melphalan/HDS. The report has been approved for oral presentation at the upcoming Regional Cancer Therapies International Symposium, to be held from February 18 – 20, 2017.
The details
The retrospective trial was performed by Moffitt Cancer Center teams in Tampa and the University of Southampton in the UK. The study assesses patient treatment results with PHP® therapy with Melphalan/HDS in subjects with primary metastatic ocular melanoma with liver metastasis cured between 2008 and 2016. The trial was directed by Dr. Alexandra Gangi.
Delcath CEO Jennifer K. Simpson, Ph.D. said that they are extremely delighted that Dr. Gangi and respective team’s research has been approved for oral presentation at this prominent event and consider that their research report will further inform on the application of Melphalan/HDS as a prospective viable additional alternative for cure of hepatic metastases in people with metastatic ocular melanoma. They look forward to reporting the details of new report after it is presented.
Delcath is an interventional oncology firm focused on advancing the therapies for primary and metastatic liver cancers. The investigational product, Melphalan Hydrochloride for application with the Delcath Hepatic Delivery System, is intended to provide high-dose chemotherapy to the liver, and at the same time controlling systemic exposure and related side effects.
The company has initiated an international Phase III FOCUS clinical study for subjects with Hepatic Dominant Ocular Melanoma and an international Phase II clinical study in the U.S. and Europe to probe the Melphalan/HDS system for the cure of primary liver cancer and intrahepatic cholangiocarcinoma. Melphalan/HDS has not been accepted by the U.S. FDA for sale in the U.S.
In the last trading session, the stock price of Delcath declined more than 24% to close the day at $0.310.
23.01.17 17:58
#79
Chalifmann3
hm,sagt mal ....
haltet ihr Delcath irgendwie für pleitegefährdet ? Wo soll das Geld für die Phase-3 Studien herkommen ? Eine KE bei dem Kurs wäre ja witzlos ?!
24.01.17 21:06
#80
Angelman
Moin
Ich mache mir schon Sorgen, obwohl offiziell alles im Plan ist. Nur die nicht erfolgte Zulassung in den USA hat das Vertrauen erschüttert.
Gerade jetzt geht der Kurs wieder gen Norgen. Knapp 50 % für den, der heute morgen rein ist. Ich bin hier dick im Minus. Nachkäufe bei 80 und 55 Cent - denke, es wird schon werden...
Gerade jetzt geht der Kurs wieder gen Norgen. Knapp 50 % für den, der heute morgen rein ist. Ich bin hier dick im Minus. Nachkäufe bei 80 und 55 Cent - denke, es wird schon werden...
24.01.17 21:30
#81
Chalifmann3
hi
da sind 11 Mio shares gehandelt,bei 2,2 mio issued and outstanding ???? das heisst die Company hat allein heute über 5 mal komplett die Besitzer gewechselt,oder ?
24.01.17 21:35
#83
Chalifmann3
hi senseo
die Angabe von 2,2 mio shares gleicht sich aber bei google und Yahoo !?
24.01.17 21:56
#86
Senseo2016
Ganz normal ist das Volumen nicht
Evtl News im Anmarsch
Die 0,46 aber gut zugestellt - da hilft nur abwarten
Die 0,46 aber gut zugestellt - da hilft nur abwarten
24.01.17 22:01
#87
Senseo2016
NICE close - hätte ich nicht gedacht
Angehängte Grafik:
bildschirmfoto_2017-01-24_um_22.png (verkleinert auf 43%)
bildschirmfoto_2017-01-24_um_22.png (verkleinert auf 43%)
24.01.17 22:01
#88
Angelman
Gut
Wir schließen nah am Tageshoch. Das macht Hoffnung auf eine nachhaltige Erholung. Das hätte mein Depot auch mal bitter nötig...
Bis Morgen!
Bis Morgen!
24.01.17 22:26
#92
Chalifmann3
hi senseo
nee,noch nicht,hatte kein Geld über,wenn das Teil am Freitag wieder um 0,30 Dollar steht,steige ich aber ein ......
25.01.17 07:02
#95
Senseo2016
AH Close 0,52
Lt meiner Anzeige wurden gestern nachbörslich noch knapp 1 Mio gehandelt
Wahnsinn!!
Wahnsinn!!
25.01.17 07:37
#96
Senseo2016
Entschuldigung
es waren 600k siehe hier:
Angehängte Grafik:
bildschirmfoto_2017-01-25_um_07.png (verkleinert auf 41%)
bildschirmfoto_2017-01-25_um_07.png (verkleinert auf 41%)
25.01.17 07:51
#97
Senseo2016
600.000 After hour ist ungefähr
der Schnitt den wir sonst am Tag hatten.
Das ist schon mehr als verdächtig
Das ist schon mehr als verdächtig
25.01.17 19:32
#98
Chalifmann3
hi
Sag mal Angelmann,da gab es doch lertztes Jahr hier einen 1:16 Resplit,davor hattest du von "deutlich 5 stelliger Stückzahl" in deinem Depot gesprochen,wieviel ist davon übrig jetzt in deinem Depot ? Und wieviel Stücklein hast du dir geangelt,senseo ? Oder bist du schon wieder raus ? Will auch nächste Woche rein ....
MFG
Chali
MFG
Chali
25.01.17 19:48
#99
Angelman
Moin
Hatte vor dem Splitt 59000, jetzt 15000...
Hoffentlich nimmt die Minusnummer noch irgendwann ein gutes ende...
Hoffentlich nimmt die Minusnummer noch irgendwann ein gutes ende...
26.01.17 03:49
#100
Chalifmann3
spinn ich ?
Habe diese News von gestern auf google gefunden,die schreiben von 480 mio Umsatz in 2015 für Delcath und von 620 mio (!) in the current quater ????? Was hälst du davon Angelmann,wieviel Umsatz macht Delcath wirklich,das ist doch absurd !
"Delcath Systems, Inc. (NASDAQ:DCTH) belonging to the Medical sector has surged 52.85% and closed its last trading session at $0.48.
The company reported its EPS on 11/11/2016. Currently, the stock has a 1 Year Price Target of $16.
Delcath Systems, Inc. on 11/11/2016 reported its EPS as $-0.66 with the analysts projecting the EPS of the stock as $-3.29. The company beat the analyst EPS Estimate with the difference of $2.63. This shows a surprise factor of 79.9%.
Many analysts have provided their estimated foresights on Delcath Systems, Inc. Earnings, with 1 analysts believing the company would generate an Average Estimate of $-3.24. Whereas they predicted High and Low Earnings Estimate as $-3.24 and $-3.24 respectively. While in the same Quarter Previous year, the Actual EPS was $-3.68.
Analysts are also projecting an Average Revenue Estimate for Delcath Systems, Inc. as $620 Million in the Current Quarter. This estimate is provided by 1 analysts. The High Revenue estimate is predicted as 620 Million, while the Low Revenue Estimate prediction stands at 620 Million. The company’s last year sales total was 439 Million.
The Company got Initiated by BioLogic Equity Research on 8-Jun-10 to Sell.
Insider Trades for Delcath Systems, Inc. show that the latest trade was made on 15 Jun 2016 where Simpson (Jennifer K), the Chief Executive Officer completed a transaction type “Sell” in which 24004 shares were traded at a price of $0.25.
1 analysts projected Price Targets for Delcath Systems, Inc.. The analysts believe that the company stock price could grow as high as $16. The Low Price target projection by analysts is $16 and the Mean Price Target is $16.
Delcath Systems, Inc. (NASDAQ:DCTH) has the market capitalization of $1.04 Million. The company rocked its 52-Week High of $6.88 on May 20, 2016 and touched its 52-Week Low of $0.3 on Jan 20, 2017. The stock has Return on Assets (ROA) of -54.7 percent. Return on Equity (ROE) stands at -221.1% and Return on Investment (ROI) of -176.9 percent.
The stock is currently showing YTD performance of -48.16 Percent. The company has Beta Value of 1.97 and ATR value of 0.15. The Weekly and Monthly Volatility stands at 38.55% and 26.32%."
"Delcath Systems, Inc. (NASDAQ:DCTH) belonging to the Medical sector has surged 52.85% and closed its last trading session at $0.48.
The company reported its EPS on 11/11/2016. Currently, the stock has a 1 Year Price Target of $16.
Delcath Systems, Inc. on 11/11/2016 reported its EPS as $-0.66 with the analysts projecting the EPS of the stock as $-3.29. The company beat the analyst EPS Estimate with the difference of $2.63. This shows a surprise factor of 79.9%.
Many analysts have provided their estimated foresights on Delcath Systems, Inc. Earnings, with 1 analysts believing the company would generate an Average Estimate of $-3.24. Whereas they predicted High and Low Earnings Estimate as $-3.24 and $-3.24 respectively. While in the same Quarter Previous year, the Actual EPS was $-3.68.
Analysts are also projecting an Average Revenue Estimate for Delcath Systems, Inc. as $620 Million in the Current Quarter. This estimate is provided by 1 analysts. The High Revenue estimate is predicted as 620 Million, while the Low Revenue Estimate prediction stands at 620 Million. The company’s last year sales total was 439 Million.
The Company got Initiated by BioLogic Equity Research on 8-Jun-10 to Sell.
Insider Trades for Delcath Systems, Inc. show that the latest trade was made on 15 Jun 2016 where Simpson (Jennifer K), the Chief Executive Officer completed a transaction type “Sell” in which 24004 shares were traded at a price of $0.25.
1 analysts projected Price Targets for Delcath Systems, Inc.. The analysts believe that the company stock price could grow as high as $16. The Low Price target projection by analysts is $16 and the Mean Price Target is $16.
Delcath Systems, Inc. (NASDAQ:DCTH) has the market capitalization of $1.04 Million. The company rocked its 52-Week High of $6.88 on May 20, 2016 and touched its 52-Week Low of $0.3 on Jan 20, 2017. The stock has Return on Assets (ROA) of -54.7 percent. Return on Equity (ROE) stands at -221.1% and Return on Investment (ROI) of -176.9 percent.
The stock is currently showing YTD performance of -48.16 Percent. The company has Beta Value of 1.97 and ATR value of 0.15. The Weekly and Monthly Volatility stands at 38.55% and 26.32%."